For example, the discovery and development of selective CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib (56, 57), have resulted in altered management of estrogen receptor–positive breast cancer (56). Here, CDK4 is linked to breast carcinoma.